1.505USD-0.33%Mkt Cap: 105.48M USDP/E: —Last update: 2026-05-26
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap105.48M USD
Enterprise Value-9.22M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-89.66M USD
Revenue/Share—
Last Price1.505 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees56
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.20
PEG—
EV/EBITDA0.12
EV/Revenue—
P/S—
P/B0.80
EPS (TTM)-1.46
EPS (Forward)-1.29
52W Range
1.0107% of range7.800
52W High7.800 USD
52W Low1.010 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-60.81%
ROA-51.55%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-81.64M USD
CapEx (TTM)264.00K USD
FCF Margin—
FCF Yield-46.68%
Net Debt-115.74M USD
Net Debt/EBITDA1.45
Balance Sheet
Debt/Equity0.12
Current Ratio14.98
Quick Ratio14.76
Book Value/Sh1.937 USD
Cash/Share1.913 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Target (Mean)10.14 USD
Target Range3.000 USD – 20.00 USD
# Analysts7
Ownership
Shares Out.69.17M
Float37.03M
Insiders0.23%
Institutions90.10%
Short Interest
Short Ratio1.3d
Short % Float6.54%
Short % Out.4.63%
Shares Short3.20M
Short (prev mo.)3.44M
Technical
SMA 502.524 (-40.4%)
SMA 2004.027 (-62.6%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)991.89K
Avg Vol (10d)859.16K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—